An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial
KalVista Pharmaceuticals, Ltd.
Emel Aygören-Pürsün; Andrea Zanichelli; Danny M Cohn; Mauro Cancian; Roman Hakl; Tamar Kinaciyan; Markus Magerl; Inmaculada Martinez-Saguer; Marcin Stobiecki; Henriette Farkas; Sorena Kiani-Alikhan; Vesna Grivcheva-Panovska; Jonathan A Bernstein; H Henry Li; Hilary J Longhurst; Paul K Audhya; Michael D Smith; Christopher M Yea; Andreas Maetzel; Daniel K Lee; Edward P Feener; Richard Gower; William R Lumry; Aleena Banerji; Marc A Riedl; Marcus Maurer